Tadalafil - Druggability Technologies

Drug Profile

Tadalafil - Druggability Technologies

Alternative Names: DRGT 99; Super-Tadalafil DRGT-99

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Druggability Technologies
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Erectile dysfunction

Most Recent Events

  • 25 Jul 2018 Phase-II clinical trials in Erectile dysfunction (PO) (Druggability Technologies pipeline, July 2018)
  • 02 May 2018 Efficacy and adverse events data from a phase I dose-escalation trial in Erectile dysfunction released by Druggability Technologies
  • 15 May 2017 Phase-I clinical trials in Erectile dysfunction (PO) before May 2017 (Druggability Technologies pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top